Injury Prevention Protocol

Overview

Most peptide protocols for tissue repair are reactive — initiated after an injury has already occurred. The injury prevention protocol takes a fundamentally different approach: using peptides proactively to support connective tissue integrity, enhance recovery from accumulated training stress, and maintain joint health before problems become symptomatic.

This approach is particularly relevant for active individuals who subject their musculoskeletal system to repetitive loading — runners, weightlifters, CrossFit athletes, martial artists, and recreational athletes in their 30s and beyond. These populations accumulate microtrauma in tendons, ligaments, and cartilage that may not produce acute symptoms but gradually degrades tissue quality over time. By the time pain appears, significant structural changes may have already occurred.

The rationale for preventive peptide use draws from the same preclinical data that supports therapeutic use. If BPC-157 accelerates tendon repair after injury, its ability to support tendon cell viability and collagen turnover is equally relevant in the absence of acute damage. If TB-500 enhances fibroblast migration in wound models, its anti-inflammatory and cell-protective properties are relevant to tissues experiencing chronic low-grade stress.

This protocol is not about healing injuries. It is about maintaining the tissue environment that prevents them.

Compounds Involved

Preventive vs Therapeutic Dosing

A key distinction in injury prevention protocols is that doses are generally at the lower end of published ranges. The goal is not to produce the maximum acute healing response but to maintain a supportive biological environment over time. Lower doses reduce cost, minimize any potential for long-term receptor adaptation, and are more sustainable for the extended cycling periods typical of preventive use.

Protocol Structure

Cycle Structure: Maintenance Cycling

Unlike therapeutic protocols that run for a defined period to address a specific injury, preventive protocols use a cycling approach that can be sustained long-term:

Standard maintenance cycle:

• ON: 4-6 weeks
• OFF: 2-4 weeks
• Repeat

This cycling pattern provides periodic support during training blocks while allowing washout periods that prevent receptor desensitization and confirm that baseline tissue health is maintained independently. See Rotation Strategy for additional cycling frameworks.

Phase 1: Assessment (Pre-Protocol)

Before initiating a preventive protocol, establish a baseline:

• Identify vulnerable areas: Which joints, tendons, or muscle groups receive the most stress from your training? Common vulnerability sites include the Achilles tendon (runners), rotator cuff (overhead athletes), patellar tendon (jumping sports), and elbow tendons (climbing, throwing).
• Baseline function testing: Range of motion, strength benchmarks, and any current low-grade discomfort levels
• Training load assessment: Current weekly training volume, intensity, and frequency
• Blood work: Baseline panel including CRP (inflammation marker) and IGF-1. See Blood Work Monitoring.

Phase 2: Active Prevention (Weeks 1-6)

BPC-157:

• 250 mcg once daily, subcutaneous
• Injection site: rotate between the subcutaneous tissue overlying the most stressed joints/tendons
• If multiple areas are of concern, alternate injection sites daily (e.g., near the left knee Monday, right shoulder Tuesday)
• Oral administration (250 mcg capsule) is a viable alternative that eliminates the need for targeted injection placement

TB-500:

• 2 mg subcutaneous, once weekly
• Standard abdominal injection site
• Lower dose and frequency compared to therapeutic use reflects the preventive intent

GHK-Cu:

• Topical application to joints and tendons receiving the highest training loads
• Apply after showering, 1-2 times daily
• Focus on superficial tendons and joints where topical penetration can reach target tissue

Phase 3: Off-Cycle (Weeks 7-10)

• Discontinue all peptides
• Continue training as normal
• Monitor for any changes in recovery, comfort levels, or performance during the off period
• This observation period confirms that tissue health is maintained and helps distinguish peptide-supported improvements from baseline adaptation

Phase 4: Reassessment and Repeat

• Compare training performance, recovery metrics, and comfort levels between on-cycle and off-cycle periods
• Adjust compound selection or dosing based on observations
• Repeat the 6-on / 4-off cycle or adjust to a schedule that aligns with your training periodization

Integration with Training Periodization

For athletes following periodized training programs, aligning peptide cycles with training phases can optimize results:

This alignment places peptide support during the periods of greatest tissue stress and uses natural training deloads as washout periods.

Optional Addition: GH Secretagogue Support

For athletes over 35-40, adding a GH secretagogue like Ipamorelin (100-200 mcg before bed) to the active prevention cycle provides systemic IGF-1 elevation that supports collagen synthesis throughout the body. This addresses the age-related decline in GH that progressively slows connective tissue turnover. See Over-40 Optimization Protocol for detailed guidance.

Important Considerations

Prevention is not treatment. If acute pain, swelling, or functional limitation develops, transition from a preventive protocol to a therapeutic protocol (see Tendon and Ligament Repair Protocol) and seek evaluation from a healthcare provider. Prevention does not eliminate injury risk — it aims to reduce it.

Training load management is the primary prevention tool. Peptides are adjuncts, not substitutes, for intelligent training programming. Sudden increases in training volume or intensity (the "too much, too soon" pattern) are the leading cause of overuse injuries and cannot be overcome by any peptide protocol.

Listen to warning signals. Persistent low-grade discomfort in a joint or tendon — especially if it worsens with training and improves with rest — is a sign of accumulating damage. Increasing peptide doses in response to this signal is the wrong approach. Reducing training load and potentially transitioning to a therapeutic protocol is the appropriate response.

Rotate injection sites when injecting near joints. Repeated subcutaneous injection at the same site can cause local tissue reactions. Rotate among 3-4 sites near the target area, and do not inject at the same location more than twice per week.

Cost-effectiveness of prevention. A preventive protocol uses lower doses over shorter cycles, making it more affordable per month than therapeutic protocols. However, the ongoing nature of the cycling means cumulative costs add up over time. See Budget-Friendly Protocol for cost management strategies.

Document everything. Track training loads, peptide administration, and tissue-specific observations (comfort, stiffness, range of motion) in your research log. Over several on/off cycles, patterns will emerge that inform individual optimization. See Research Documentation Protocol.

Disclaimer

This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Peptides discussed here are research compounds and may not be approved for human use in all jurisdictions. Always consult a qualified healthcare provider before beginning any new protocol. Injury prevention is multifactorial and no single intervention can eliminate injury risk. Individual responses vary, and the information presented here reflects preclinical and anecdotal data rather than established clinical guidelines.